Diabetic lung disease: fact or fiction?

1.

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.PubMed

2.

NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387:1513–30.

3.

International Federation Diabetes. Diabetes Atlas. 6th ed. International Diabetes federation. 2013;28:49.

4.

American Diabetes Association. Diabetes Care. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. 2018;41:13–27.

5.

Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care. 2016;39:686–93.

6.

Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med. 2009;360:1646–54.PubMed

7.

Greenhill C. Unravelling metformin's mechanism of action. Nat Rev Endocrinol. 2018;14:564.PubMed

8.

Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60:1577–85.PubMedPubMedCentral

9.

Pitocco D, Fuso L, Conte EG, Zaccardi F, Condoluci C, Scavone G, et al. The diabetic lung-a new target organ? Rev Diabet Stud. 2012;9:23–35.PubMedPubMedCentral

10.

Lange P, Groth S, Kastrup J, Mortensen J, Appleyard M, Nyboe J, et al. Diabetes mellitus, plasma glucose and lung function in a cross-sectional population study. Eur Respir J. 1989;2:14–9.PubMed

11.

Singh S, Prakash YS, Linneberg A, Agrawal A. Insulin and the lung: connecting asthma and metabolic syndrome. J Allergy (Cairo). 2013;2013:627384.

12.

Bottini P, Scionti L, Santeusanio F, Casucci G, Tantucci C. Impairment of the respiratory system in diabetic autonomic neuropathy. Diabetes Nutr Metab. 2000;13:165–72.PubMed

13.

Forgiarini LA Jr, Kretzmann NA, Porawski M, Dias AS, Marroni NA. Experimental diabetes mellitus: oxida oxidative stress and changes in lung structure. J Bras Pneumol. 2009;35:788–91.PubMed

14.

Hsia CC, Raskin P. The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am J Med. 2005;118:205–11.PubMed

15.

Kuziemski K, Specjalski K, Jassem E. Diabetic pulmonary microangiopathy - fact or fiction? Endokrynol Pol. 2011;62:171–6.PubMed

16.

Soulis T, Thallas V, Youssef S, Gilbert RE, McWilliam BG, Murray-McIntosh RP, et al. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia. 1997;40:619–28.PubMed

17.

Soulis T, Cooper ME, Sastra S, Thallas V, Panagiotopoulos S, Bjerrum OJ, et al. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia. 1997;40:1141–51.PubMed

18.

Hamlin CR, Kohn RR, Luschin JH. Apparent accelerated aging of human collagen in diabetes mellitus. Diabetes. 1975;24:902–4.PubMed

19.

Cavan DA, Parkes A, O’Donnell MJ, Freeman W, Cayton RM. Lung function and diabetes. Respir Med. 1991;85:257–8.PubMed

20.

Ofulue AF, Thurlbeck WM. Experimental diabetes and the lung. II. In vivo connective tissue metabolism. Am Rev Respir Dis. 1988;138:284–9.PubMed

21.

Kida K, Fujino Y. Lung structure and elastic recoil properties in hereditary diabetes mellitus in KK-mice, C57 black mice, and F1 hybrids. J Lab Clin Med. 1993;122:524–32.PubMed

22.

Foster DJ, Ravikumar P, Bellotto DJ, Unger RH, Hsia CC. Fatty diabetic lung: altered alveolar structure and surfactant protein expression. Am J Physiol Lung Cell Mol Physiol. 2010;298:392–403.

23.

Treviño-Alanís M, Ventura-Juárez J, Hernández-Piñero J, Nevárez-Garza A, Quintanar-Stephano A, González-Piña A. Delayed lung maturation of foetus of diabetic mother rats develop with a diminish, but without changes in the proportion of type I and II pneumocytes, and decreased expression of protein D-associated surfactant factor, Anat. Histol. Embryol. 2009;38:169–76.

24.

Heimer D, Brami J, Lieberman D, Bark H. Respiratory muscle performance in patients with type 1 diabetes. Diabet Med. 1990;7:434–7.PubMed

25.

Fuso L, Pitocco D, Longobardi A, Zaccardi F, Contu C, Pozzuto C, et al. Reduced respiratory muscle strength and endurance in type 2 diabetes mellitus. Diabetes Metab Res Rev. 2012;28:370–5.PubMed

26.

Schuyler MR, Niewoehner DE, Inkley SR, Kohn R. Abnormal lung elasticity in juvenile diabetes mellitus. Am Rev Respir Dis. 1976;113:37–41.PubMed

27.

Davis WA, Knuiman M, Kendall P, Grange V, Davis TM. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle diabetes study. Diabetes Care. 2004;27:752–7.PubMed

28.

Lange P, Groth S, Mortensen J, Appleyard M, Nyboe J, Schnohr P, et al. Diabetes mellitus and ventilatory capacity: a five year follow-up study. Eur Respir J. 1990;3:288–92.PubMed

29.

Antonelli Incalzi R, Fuso L, Pitocco D, Basso S, Trove A, Longobardi A, et al. Decline of neuroadrenergic bronchial innervation and respiratory function in type 1 diabetes mellitus: a longitudinal study. Diabetes Metab Res Rev. 2007;23:311–6.PubMed

30.

Weiss SR, Cheng SL, Kourides IA, Gelfand RA, Landschulz WH. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med. 2003;163:2277–82.PubMed

31.

Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care. 2005;28:1630–5.PubMed

32.

McKeever TM, Weston PJ, Hubbard R, Fogarty A. Lung function and glucose metabolism: an analysis of data from the third National Health and nutrition examination survey. Am J Epidemiol. 2005;161:546–56.PubMed

33.

Lawlor DA, Ebrahim S, Smith GD. Associations of measures of lung function with insulin resistance and type 2 diabetes: findings from the British Women's heart and health study. Diabetologia. 2004;47:195–203.PubMed

34.

Yeh HC, Punjabi NM, Wang NY, Pankow JS, Duncan BB, Cox CE, et al. Crosssectional and prospective study of lung function in adults with type 2 diabetes: the atherosclerosis risk in communities (ARIC) study. Diabetes Care. 2008;31:741–6.PubMed

35.

Guvener N, Tutuncu BN, Akcay S, Eyuboglu F, Gokcel A. Alveolar gas exchange in patients with type 2 diabetes mellitus. Endocr J. 2003;50:663–7.PubMed

36.

Klein OL, Kalhan R, Williams MV, Tipping M, Lee J, Peng J, et al. Lung spirometry parameters and diffusion capacity are decreased in patients with type 2 diabetes. Diabet Med. 2012;29:212–9.PubMed

37.

Ozsahin K, Tugrul A, Mert S, Yüksel M, Tugrul G. Evaluation of pulmonary alveolo-capillary permeability in type 2 diabetes mellitus: using technetium 99mTc-DTPA aerosol scintigraphy and carbon monoxide diffusion capacity. J Diabetes Complicat. 2006;20:205–9.

38.

Wheatley CM, Baldi JC, Cassuto NA, Foxx-Lupo WT, Snyder EM. Glycemic control influences lung membrane diffusion and oxygen saturation in exercise-trained subjects with type 1 diabetes: alveolar-capillary membrane conductance in type 1 diabetes. Eur J Appl Physiol. 2011;111:567–78.PubMed

39.

Pitocco D, Santangeli P, Fuso L, Zaccardi F, Longobardi A, Infusino F, et al. Association between reduced pulmonary diffusing capacity and cardiac autonomic dysfunction in type 1 diabetes. Diabet Med. 2008;25:1366–9.PubMed

40.

Nishimura M, Miyamoto K, Suzuki A, Yamamoto H, Tsuji M, Kishi F, et al. Ventilatory and heart responses to hypoxia and hypercapnia in patients with diabetes mellitus. Thorax. 1989;44:251–7.PubMedPubMedCentral

41.

Weisbrod CJ, Eastwood PR, O’Driscoll GO, Green DJ. Abnormal ventilatory responses to hypoxia in type 2 diabetes. Diabet Med. 2005;22:563–8.PubMed

42.

Antonelli Incalzi R, Fuso L, Giordano A, Pitocco D, Maiolo C, Calcagni ML, et al. Neuroadrenergic denervation of the lung in type I diabetes mellitus complicated by autonomic neuropathy. Chest. 2002;121:443–51.PubMed

43.

Santos e Fonseca CM, Manco JC, Gallo Junior L, Barreira AA, Foss MC. Cholinergic bronchomotor tone and airway caliber in insulin-dependent diabetes mellitus. Chest. 1992;101:1038–43.PubMed

44.

Koziel H, Koziel MJ. Pulmonary complications of diabetes mellitus. Pneumonia Infect Dis Clin North Am. 1995;9:65–96.PubMed

45.

Vojtková J, Ciljaková M, Michnová Z, Turčan T. Chronic complications of diabetes mellitus related to the respiratory system. Pediatr Endocrinol Diabetes Metab. 2012;18:112–5.PubMed

46.

Scano G, Seghieri G, Mancini M, Filippelli M, Duranti R, Fabbri A, et al. Dyspnoea, peripheral airway involvement and respiratory muscle effort in patients with type I diabetes mellitus under good metabolic control. Clin Sci (Lond). 1999;96:499–506.

47.

Wanke T, Formanek D, Auinger M, Popp W, Zwick H, Irsigler K. Inspiratory muscle performance and pulmonary function changes in insulin-dependent diabetes mellitus. Am Rev Respir Dis. 1991;143:97–100.PubMed

48.

Villa MP, Cacciari E, Bernardi F, Cicognani A, Salardi S, Zapulla F. Bronchial reactivity in diabetic patients. Relationship to duration of diabetes and degree of glycemic control. Am J Dis Child. 1988;142:726–9.PubMed

49.

Wanke TH, Formanek D, Auginer M, Zwick H, Irsigler K. Pulmonary gas exchange and oxygen uptake during exercise in patients with type 1 diabetes mellitus. Diabet Med. 1992;9:252–7.PubMed

50.

Brassard P, Ferland A, Bogaty P, Desmeules M, Jobin J, Poirier P. Influence of glycemic control on pulmonary function and heart rate in response to exercise in subjects with type 2 diabetes mellitus. Metabolism. 2006;55:1532–7.PubMed

51.

Ardigo D, Valtuena S, Zavaroni I, Baroni MC, Delsignore R. Pulmonary complications of diabetes mellitus: the role of glycemic control. Curr Drug Targets Inflamm Allergy. 2004;3:455–8.PubMed

52.

Wolff SP, Dean RT. Glucose autoxidation and protein modification; potential role of autoxidative glycosylation in diabetes. Biochem J. 1987;245:243–50.PubMedPubMedCentral

53.

Goldman MD. Lung dysfunction in diabetes. Diabetes Care. 2003;26:1915–8.PubMed

54.

Hsia CC, Raskin P. Lung function changes related to diabetes mellitus. Diabetes Technol Ther. 2007;9:73–82.

55.

Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst. 1999;91:542–7.PubMed

56.

Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Adami HO. Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer. 1997;71:360–3.PubMed

57.

Larsson SC, Wolk A. Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia. 2011;54:1013–8.PubMed

58.

Chow WH, Gridley G, Nyren O, Linet MS, Ekbom A, Fraumeni JF Jr, et al. Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst. 1995;87:930–1.PubMed

59.

Argiles JM, Lopez-Soriano FJ. Insulin and cancer (review). Int J Oncol. 2001;18:683–7.PubMed

60.

Kim WY, Jin Q, Oh SH, Kim ES, Yang YJ, Lee DH, et al. Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res. 2009;69:7439–48.PubMedPubMedCentral

61.

Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674–85.PubMedPubMedCentral

62.

Ruano-Ravina A, Figueiras A, Barros-Dios JM. Lung cancer and related risk factors: an update of the literature. Public Health. 2003;117:149–56.PubMed

63.

Strickler HD, Wylie-Rosett J, Rohan T, Hoover DR, Smoller S, Burk RD, et al. The relation of type 2 diabetes and cancer. Diabetes Technol Ther. 2001;3:263–74.PubMed

64.

Wakai K, Ito Y, Suzuki K, Tamakoshi A, Seki N, Ando M, et al. Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death: a case-control study nested in the Japan collaborative cohort (JACC) study. Jpn J Cancer Res. 2002;93:1279–86.PubMedPubMedCentral

65.

Ehrlich SF, Quesenberry CP Jr, Van Den Eeden SK, Shan J, Ferrara A. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care. 2010;33:55–60.PubMed

66.

Hall GC, Roberts CM, Boulis M, Mo J, MacRae KD. Diabetes and the risk of lung cancer. Diabetes Care. 2005;28:590–4.PubMed

67.

Lee JY, Jeon I, Lee JM, Yoon JM, Park SM. Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies. Eur J Cancer. 2013;49:2411–23.PubMed

68.

Dankner R, Boker LK, Boffetta P, Balicer RD, Murad H, Berlin A, et al. A historical cohort study on glycemic-control and cancer-risk among patients with diabetes. Cancer Epidemiol. 2018;57:104–9.PubMed

69.

De Giorgio R, Barbara G, Cecconi A, Corinaldesi R, Mancini AM. Diabetes is associated with longer survival rates in patients with malignant tumors. Arch Intern Med. 2000;160:2217.PubMed

70.

Hatlen P, Grønberg BH, Langhammer A, Carlsen SM, Amundsen T. Prolonged survival in patients with lung cancer with diabetes mellitus. J Thorac Oncol. 2011;6:1810–7.PubMed

71.

Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Emerging risk factors collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41.PubMedPubMedCentral

72.

Vasic L. Locally advanced non-small cell lung cancer—pretreatment prognostic factors: disease stage, tumor histopathological characteristics, the patient-related factors. Arch Oncol. 2007;15:19–23.

73.

Karlin NJ, Amin SB, Buras MR, Kosiorek HE, Verona PM, Cook CB. Patient outcomes from lung cancer and diabetes mellitus: a matched case-control study. Future Sci OA. 2017;4:FSO248.PubMedPubMedCentral

74.

Satoh H, Ishikawa H, Kurishima K, Ohtsuka M, Sekizawa K. Diabetes is not associated with longer survival in patients with lung cancer. Arch Intern Med. 2001;161:485.PubMed

75.

Xu T, Li D, He Y, Zhang F, Qiao M, Chen Y. Prognostic value of metformin for non-small cell lung cancer patients with diabetes. World J Surg Oncol. 2018;16:60.PubMedPubMedCentral

76.

Tsai MJ, Yang CJ, Kung YT, Sheu CC, Shen YT, Chang PY, et al. Metformin decreases lung cancer risk in diabetic patients in a dose-dependent manner. Lung Cancer. 2014;86:137–43.PubMed

77.

Lin JJ, Gallagher EJ, Sigel K, Mhango G, Galsky MD, Smith CB, et al. Survival of patients with stage IV lung cancer with diabetes treated with metformin. Am J Respir Crit Care Med. 2015;191:448–54.PubMedPubMedCentral

78.

Ferrara A, Lewis JD, Quesenberry CP Jr, Peng T, Strom BL, Van Den Eeden SK, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care. 2011;34:923–9.PubMedPubMedCentral

79.

Smiechowski BB, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care. 2013;36:124–9.PubMed

80.

Nie SP, Chen H, Zhuang MQ, Lu M. Anti-diabetic medications do not influence risk of lung cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2014;15:6863–9.PubMed

81.

Valerius N, Eff C, Hansen NE, Karle H, Nerup J, Søeberg B, et al. Neutrophil and lymphocyte function in patients with diabetes mellitus. Acta Med Scand. 1982;211:463–72.PubMed

82.

Bhargava P, Lee CH. Role and function of macrophages in the metabolic syndrome. Biochem J. 2012;442:253–62.PubMed

83.

Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41:281–8.PubMed

84.

Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 2007;23:3–13.PubMed

85.

Fernández-Real JM, Valdés S, Manco M, Chico B, Botas P, Campo A, et al. Surfactant protein d, a marker of lung innate immunity, is positively associated with insulin sensitivity. Diabetes Care. 2010;33:847–53.PubMedPubMedCentral

86.

Baker EH, Baines DL. Airway glucose homeostasis: a new target in the prevention and treatment of pulmonary infection. Chest. 2018;153:507–14.PubMed

87.

Nirmal J, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med. 1999;341:1906–12.

88.

Higa M. Clinical epidemiology of fungal infection in diabetes. Nihon Rinsho. 2008;66:2239–44.PubMed

89.

Diepersloot RJ, Bouter KP, Beyer WE, Hoekstra JB, Masurel N. Humoral immune response and delayed type hypersensitivity to influenza vaccine in patients with diabetes mellitus. Diabetologia. 1987;30:397–401.PubMed

90.

Kornum JB, Thomsen RW, Riis A, Lervang HH, Schønheyder HC, Sørensen HT. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population- based case-control study. Diabetes Care. 2008;31:1541–5.PubMedPubMedCentral

91.

Falguera M, Pifarre R, Martin A, Sheikh A, Moreno A. Etiology and outcome of community-acquired pneumonia in patients with diabetes mellitus. Chest. 2005;128:3233–9.PubMed

92.

Bader MS, Abouchehade KA, Yi Y, Haroon B, Bishop LD, Hawboldt J. Antibiotic administration longer than eight hours after triage and mortality of community-acquired pneumonia in patients with diabetes mellitus. Eur J Clin Microbiol Infect Dis. 2011;30:881–6.PubMed

93.

van de Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM, Leufkens HG. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax. 2006;61:957–61.PubMedPubMedCentral

94.

van de Garde EM, Souverein PC, Hak E, Deneer VH, van den Bosch JM, Leufkens HG. Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes. J Hypertens. 2007;25:235–9.PubMed

95.

Seminog OO, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people hospitalized with diabetes mellitus: English record-linkage studies. Diabet Med. 2013;30:1412–9.PubMed

96.

Harries AD, Lin Y, Satyanarayana S, Lönnroth K, Li L, Wilson N, et al. The looming epidemic of diabetes-associated tuberculosis: learning lessons from the HIV-associated tuberculosis. Inter J Tuberc Lung Dis. 2011;15:1436–45.

97.

Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5:e152.PubMedPubMedCentral

98.

Restrepo BI, Schlesinger LS. Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus. Tuberculosis. 2013;93:10–4.

99.

Singla R, Khan N, Al Sharif N, Ai-Sayegh MO, Shaikh MA, Osman MM. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. Int J Tuberc Lung Dis. 2006;10:74–9.PubMed

100.

Restrepo BI, Fisher-Hoch SP, Crespo JG, Whitney E, Perez A, Smith B, et al. Nuevo Santander tuberculosis trackers. Cross-sectional assessment reveals high diabetes prevalence among newly-diagnosed tuberculosis cases. Bull World Health Organ. 2011;89:352–9.PubMedPubMedCentral

101.

Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9:737–46.PubMedPubMedCentral

102.

Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81.PubMedPubMedCentral

103.

Delgado-Sánchez G, García-García L, Castellanos-Joya M, Cruz-Hervert P, Ferreyra-Reyes L, Ferreira-Guerrero E, et al. Association of Pulmonary Tuberculosis and Diabetes in Mexico: analysis of the National Tuberculosis Registry 2000-2012. PLoS One. 2015;10:e0129312.PubMedPubMedCentral

104.

Guirado E, Schlesinger LS, Kaplan G. Macrophages in tuberculosis: friend or foe. Semin Immunopathol. 2013;35:563–83.PubMedPubMedCentral

105.

Repasy T, Lee J, Marino S, Martinez N, Kirschner DE, Hendricks G, et al. Intracellular bacillary burden reflects a burst size for Mycobacterium tuberculosis In vivo. PLoS Pathog. 2013;9:e1003190.PubMedPubMedCentral

106.

Gomez DI, Twahirwa M, Schlesinger LS, Restrepo BI. Reduced Mycobacterium tuberculosis association with monocytes from diabetes patients that have poor glucose control. Tuberculosis. 2013;93:192–7.PubMed

107.

Restrepo BI, Twahirwa M, Rahbar MH, Schlesinger LS. Phagocytosis via complement or fc-gamma receptors is compromised in monocytes from type 2 diabetes patients with chronic hyperglycemia. PLoS One. 2014;26(9):e92977.

108.

Musilli C, Paccosi S, Pala L, Gerlini G, Ledda F, Mugelli A, et al. Characterization of circulating and monocyte-derived dendritic cells in obese and diabetic patients. Mol Immunol. 2011;49:234–8.PubMed

109.

Zhang Q, Xiao HP, Cui HY, Sugawara I. Significant increase in natural-killer T cells in patients with tuberculosis complicated by type 2 diabetes mellitus. J Int Med Res. 2011;39:105–11.PubMed

110.

Al-Attiyah RJ, Mustafa AS. Mycobacterial antigen-induced T helper type 1 (Th1) and Th2 reactivity of peripheral blood mononuclear cells from diabetic and non-diabetic tuberculosis patients and Mycobacterium bovis bacilli Calmette-Gue´ rin (BCG)–vaccinated healthy subjects. Clin Exp Immunol. 2009;158:64–73.PubMedPubMedCentral

111.

Stalenhoef JE, Alisjahbana B, Nelwan EJ, van der Ven-Jongekrijg J, Ottenhoff TH, van der Meer JW, et al. The role of interferon-g in the increased tuberculosis risk in type 2 diabetes mellitus. Eur J Clin Microbiol Infect Dis. 2008;27:97–103.PubMed

112.

Restrepo BI, Fisher-Hoch SP, Pino PA, Salinas A, Rahbar MH, Mora F, et al. Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. Clin Infect Dis. 2008;47:634–41.PubMed

113.

Kumar NP, Sridhar R, Banurekha VV, Jawahar MS, Nutman TB, Babu S. Expansion of pathogen-specific Th1 and Th17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus. J Infect Dis. 2013;208:739–48.PubMedPubMedCentral

114.

Kumar NP, Sridhar R, Banurekha VV, Jawahar MS, Fay MP, Nutman TB, et al. Type 2 diabetes mellitus coincident with pulmonary tuberculosis is associated with heightened systemic type 1, type 17 and other proinflammatory cytokines. Ann Am Thorac Soc. 2013;10:441–9.PubMedPubMedCentral

115.

Kumar NP, Sridhar R, Nair D, Banurekha VV, Nutman TB, Babu S. Type 2 diabetes mellitus is associated with altered CD8(+) T and natural killer cell function in pulmonary tuberculosis. Immunology. 2015;144:677–86.PubMedPubMedCentral

116.

Blackman SM, Hsu S, Vanscoy LL, Collaco JM, Ritter SE, Naughton K, et al. Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis. J Clin Endocrinol Metab. 2009;94:1302–9.PubMedPubMedCentral

117.

Lewis C, Blackman SM, Nelson A, Oberdorfer E, Wells D, Dunitz J, et al. Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med. 2015;191:194–200.PubMedPubMedCentral

118.

van den Berg JM, Morton AM, Kok SW, Pijl H, Conway SP, Heijerman HG. Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD). J Cyst Fibros. 2008;7:515–9.PubMed

119.

Rosenecker J, Höfler R, Steinkamp G, Eichler I, Smaczny C, Ballmann M, et al. Diabetes mellitus in patients with cystic fibrosis: the impact of diabetes mellitus on pulmonary function and clinical outcome. Eur J Med Res. 2001;6:345–50.PubMed

120.

Koch C, Rainisio M, Madessani U, Harms HK, Hodson ME, Mastella G, et al. Investigators of the European epidemiologic registry of cystic fibrosis. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European epidemiologic registry of cystic fibrosis. Pediatr Pulmonol. 2001;32:343–50.PubMed

121.

Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 2000;162:891–5.PubMed

122.

Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr. 1992;151:684–7.PubMed

123.

Rolon MA, Benali K, Munck A, Navarro J, Clement A, Tubiana-Rufi N, et al. Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr. 2001;90:860–7.PubMed

124.

Hameed S, Morton JR, Field PI, Belessis Y, Yoong T, Katz T, et al. Once daily insulin detemir in cystic fibrosis with insulin deficiency. Arch Dis Child. 2012;97:464–7.PubMed

125.

Mozzillo E, Franzese A, Valerio G, Sepe A, De Simone I, Mazzarella G, et al. One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatr Diabetes. 2009;10:162–7.PubMed

126.

Nousia-Arvanitakis S, Galli-Tsinopoulou A, Karamouzis M. Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus. Acta Paediatr. 2001;90:515–9.PubMed

127.

Dobson L, Hattersley AT, Tiley S, Elworthy S, Oades PJ, Sheldon CD. Clinical improvement in cystic fibrosis with early insulin treatment. Arch Dis Child. 2002;87:430–1.PubMedPubMedCentral

128.

Limoli DH, Yang J, Khansaheb MK, Helfman B, Peng L, Stecenko AA, et al. Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes. Eur J Clin Microbiol Infect Dis. 2016;35:947–53.PubMed

129.

Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. Nat Rev Immunol. 2015;15:57–65.PubMedPubMedCentral

130.

Douek IF, Leech NJ, Gillmor HA, Bingley PJ, Gale EA. Children with type 1 diabetes and their unaffected siblings have fewer symptoms of asthma. Lancet. 1999;353:1850.PubMed

131.

Dahlqvist G, Patterson C, Soltesz G. Decreased prevalence of atopic diseases in children with diabetes. The EURODIAB substudy 2 study group. J Pediatr. 2000;137:470–4.

132.

Meerwaldt R, Odink RJ, Landaeta R, Aarts F, Brunekreef B, Gerritsen J, et al. A lower prevalence of atopy symptoms in children with type 1 diabetes mellitus. Clin Exp Allergy. 2002;32:254–5.PubMed

133.

Cardwell CR, Shields MD, Carson DJ, Patterson CC. A metaanalysis of the association between childhood type 1 diabetes and atopic disease. Diabetes Care. 2003;26:2568–74.PubMed

134.

Metsälä J, Lundqvist A, Virta LJ, Kaila M, Gissler M, Virtanen SM, et al. The association between asthma and type 1 diabetes: a paediatric case-cohort study in Finland, years 1981-2009. Int J Epidemiol. 2018;47:409–16.PubMed

135.

Stene LC, Nafstad P. Relation between occurrence of type 1 diabetes and asthma. Lancet. 2001;357:607–8.PubMed

136.

Kero J, Gissler M, Hemminki E, Isolauri E. Could Th1 and Th2 diseases coexist? Evaluation of asthma incidence in children with coeliac disease, type 1 diabetes, or rheumatoid arthritis: a register study. J Allergy Clin Immunol. 2001;108:781–3.PubMed

137.

Hsiao YT, Cheng WC, Liao WC, Lin CL, Shen TC, Chen WC, et al. Type 1 diabetes and increased risk of subsequent asthma: a Nationwide population-based cohort study. Medicine (Baltimore). 2015;94:e1466.

138.

Kondrashova A, Seiskari T, Ilonen J, Knip M, Hyöty H. The 'Hygiene hypothesis' and the sharp gradient in the incidence of autoimmune and allergic diseases between Russian Karelia and Finland. APMIS. 2013;121:478–93.PubMed

139.

Black MH, Anderson A, Bell RA, Dabelea D, Pihoker C, Saydah S, et al. Prevalence of asthma and its association with glycemic control among youth with diabetes. Pediatrics. 2011;128:839–47.

140.

Rachmiel M, Bloch O, Bistritzer T, Weintrob N, Ofan R, Koren-Morag N, et al. TH1/TH2 cytokine balance in patients with both type 1 diabetes mellitus and asthma. Cytokine. 2006;34:170–6.PubMed

141.

Rachmiel M, Bloch O, Shaul AA, Ben-Yehudah G, Bistritzer Z, Weintrob N, et al. Young patients with both type 1 diabetes mellitus and asthma have a unique IL-12 and IL-18 secretory pattern. Pediatr Diabetes. 2011;12:596–603.PubMed

142.

Kolahian S, Asadi F, Nassiri SM. Airway inflammatory events in diabetic-antigen sensitized Guinea pigs. Eur J Pharmacol. 2011;659:252–8.PubMed

143.

Cavalher-Machado SC, de Lima WT, Damazo AS, de Frias Carvalho V, Martins MA, de Silva PM, Sannomiya P. Down-regulation of mast cell activation and airway reactivity in diabetic rats: role of insulin. Eur Respir J 2004;24:552–558.

144.

Szilvássy J, Sziklai I, Horvath P, Szilasi M, Németh J, Kovács P, et al. Feeble bronchomotor responses in diabetic rats in association with decreased sensory neuropeptide release. Am J Physiol Lung Cell Mol Physiol. 2002;282:1023–30.

145.

Belmonte K, Jacoby D, Fryer A. Increased function of inhibitory neuronal M2 muscarinic receptors in diabetic rat lungs. Br J Pharmacol. 1997;121:1287–94.PubMedPubMedCentral

146.

Belmonte K, Fryer A, Costello R. Role of insulin in antigen-induced airway eosinophilia and neuronal M2 muscarinic receptor dysfunction. J Appl Physiol. 1998;85:1708–18.PubMed

147.

Lee EJ, In KH, Ha ES, Lee KJ, Hur GY, Kang EH, et al. Asthma-like symptoms are increased in the metabolic syndrome. J Asthma. 2009;46:339–42.PubMed

148.

Thuesen BH, Husemoen LL, Hersoug LG, Pisinger C, Linneberg A. Insulin resistance as a predictor of incident asthma-like symptoms in adults. Clin Exp Allergy. 2009;39:700–7.PubMed

149.

Ma J, Xiao L, Knowles SB. Obesity, insulin resistance and the prevalence of atopy and asthma in US adults. Allergy. 2010;65:1455–63.PubMed

150.

Husemoen LL, Glümer C, Lau C, Pisinger C, Mørch LS, Linneberg A. Association of obesity and insulin resistance with asthma and aeroallergen sensitization. Allergy. 2008;63:575–82.PubMed

151.

Movahed M, Hashemzadeh M, Jamal M. Increased prevalence of asthma in patients with type 2 diabetes mellitus. Chest. 2006;130:160S.

152.

Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: a metaanalysis of prospective epidemiologic studies. Am J Respir Crit Care Med. 2007;175:661–6.PubMedPubMedCentral

153.

Pradeepan S, Garrison G, Dixon AE. Obesity in asthma: approaches to treatment. Curr Allergy Asthma Rep. 2013;13:434–42.PubMedPubMedCentral

154.

Azad MB, Becker AB, Kozyrskyj AL. Association of maternal diabetes and child asthma. Pediatr Pulmonol. 2013;48(6):545–52.PubMed

155.

Scholtens S, Wijga AH, Brunekreef B, Kerkhof M, Postma DS, Oldenwening M, et al. Maternal overweight before pregnancy and asthma in offspring followed for 8 years. Int J Obes. 2010;34:606–13.

156.

Viardot A, Grey ST, Mackay F, Chisholm D. Potential antiinflammatory role of insulin via the preferential polarization of effector T cells toward a T helper 2 phenotype. Endocrinology. 2007;148:346–53.PubMed

157.

Lessmann E, Grochowy G, Weingarten L, Giesemann T, Aktories K, Leitges M, et al. Insulin and insulin-like growth factor-1 promote mast cell survival via activation of the phosphatidylinositol-3-kinase pathway. Exp Hematol. 2006;34:1532–41.PubMed

158.

Noveral JP, Bhala A, Hintz RL, Grunstein MM, Cohen P. Insulin-like growth factor axis in airway smooth muscle cells. Am J Phys. 1994;267:761–5.

159.

Gosens R, Nelemans SA, Hiemstra M, Grootte Bromhaar MM, Meurs H, Zaagsma J. Insulin induces a hypercontractile airway smooth muscle phenotype. Eur J Pharmacol. 2003;481:125–31.PubMed

160.

Gosens R, Schaafsma D, Meurs H, Zaagsma J, Nelemans SA. Role of rho-kinase in maintaining airway smooth muscle contractile phenotype. Eur J Pharmacol. 2004;483:71–8.PubMed

161.

Mirrakhimov AE. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony. Cardiovasc Diabetol. 2012;11:132.PubMedPubMedCentral

162.

Kinney GL, Black-Shinn JL, Wan ES, Make B, Regan E, Lutz S, et al. COPDGene investigators. Pulmonary function reduction in diabetes with and without chronic obstructive pulmonary disease. Diabetes Care. 2014;37:389–95.PubMedPubMedCentral

163.

Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32:962–9.PubMed

164.

Miller J, Edwards LD, Agustí A, Bakke P, Calverley PM, Celli B, et al. Evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) investigators. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107:1376–84.PubMed

165.

Baker EH, Janaway CH, Philips BJ, Brennan AL, Baines DL, Wood DM, et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax. 2006;61:284–9.PubMedPubMedCentral

166.

Chakrabarti B, Angus RM, Agarwal S, Lane S, Calverley PM. Hyperglycaemia as a predictor of outcome during non-invasive ventilation in decompensated COPD. Thorax. 2009;64:857–62.PubMed

167.

Mamillapalli C, Tentu R, Jain NK, Bhandari R. COPD and type 2 diabetes. Curr Respir Med Rev. 2019;15:1–8.

168.

Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 2010;80:112–9.PubMed

169.

Lee T, Mao IC, Lin CH, Lin SH, Hsieh MC. Chronic obstructive pulmonary disease: a risk factor for type 2 diabetes: a nationwide population-based study. Eur J Clin Investig. 2013;43:1113–9.

170.

Lindberg A, Larsson LG, Rönmark E, Lundbäck B. Co-morbidity in mild-to-moderate COPD: comparison to normal and restrictive lung function. COPD. 2011;8:421–8.PubMed

171.

Joo H, Park J, Lee SD, Oh YM. Comorbidities of chronic obstructive pulmonary disease in Koreans: a population-based study. J Korean Med Sci. 2012;27:901–6.PubMedPubMedCentral

172.

O'Byrne PM, Rennard S, Gerstein H, Radner F, Peterson S, Lindberg B, et al. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir Med. 2012;106:1487–93.PubMed

173.

Habib G, Dar-Esaif Y, Bishara H, Artul S, Badarny S, Chernin M, et al. The impact of corticosteroid treatment on hemoglobin A1C levels among patients with type-2 diabetes with chronic obstructive pulmonary disease exacerbation. Respir Med. 2014;108:1641–6.PubMed

174.

Bishwakarma R, Zhang W, Lin YL, Kuo YF, Cardenas VJ, Sharma G. Metformin use and health care utilization in patients with coexisting chronic obstructive pulmonary disease and diabetes mellitus. Int J Chron Obstruct Pulmon Dis. 2018;13:793–800.PubMedPubMedCentral

175.

Yen FS, Chen W, Wei JC, Hsu CC, Hwu CM. Effects of metformin use on total mortality in patients with type 2 diabetes and chronic obstructive pulmonary disease: a matched-subject design. PLoS One. 2018;13:e0204859.PubMedPubMedCentral

176.

Yu S, Christiani DC, Thompson BT, Bajwa EK, Gong MN. Role of diabetes in the development of acute respiratory distress syndrome. Crit Care Med. 2013;41:2720e2732.

177.

Singla A, Turner P, Pendurthi MK, Agrawal V, Modrykamien A. Effect of type II diabetes mellitus on the outcomes in patients with acute respiratory distress syndrome. J Crit Care. 2014;29:66e69.

178.

Boyle AJ, Madotto F, Laffey JG, Bellani G, Pham T, Pesenti A, et al. ESICM trials group. Identifying associations between diabetes and acute respiratory distress syndrome in patients with acute hypoxemic respiratory failure: an analysis of the LUNG SAFE database. Crit Care. 2018;22:268.PubMedPubMedCentral

179.

Esper A, Moss M. Diabetes and acute respiratory distress syndrome: can we finally believe the epidemiology? Crit Care Med. 2013;41:2822–3.PubMed

180.

Kor DJ, Warner DO, Alsara A, Fernández-Pérez ER, Malinchoc M, Kashyap R, et al. Derivation and diagnostic accuracy of the surgical lung injury prediction model. Anesthesiology. 2011;115:117–28.PubMed

181.

Koh GC, Vlaar AP, Hofstra JJ, de Jong HK, van Nierop S, Peacock SJ, et al. In the critically ill patient, diabetes predicts mortality independent of statin therapy but is not associated with acute lung injury: a cohort study. Crit Care Med. 2012;40:1835–43.PubMedPubMedCentral

182.

Moss M, Guidot DM, Steinberg KP, Duhon GF, Treece P, Wolken R, et al. Diabetic patients have a decreased incidence of acute respiratory distress syndrome. Crit Care Med. 2000;28:2187–92.PubMed

183.

Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, Christiani DC. Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion. Crit Care Med. 2005;33:1191–8.PubMed

184.

Iscimen R, Cartin-Ceba R, Yilmaz M, Khan H, Hubmayr RD, Afessa B, et al. Risk factors for the development of acute lung injury in patients with septic shock: An observational cohort study. Crit Care Med. 2008;36:1518–22.PubMed

185.

Trillo-Alvarez C, Cartin-Ceba R, Kor DJ, Kojicic M, Kashyap R, Thakur S, et al. Acute lung injury prediction score: derivation and validation in a population-based sample. Eur Respir J. 2011;37:604–9.PubMed

186.

Dabbagh O, Park PK, Adesanya A, Chang SY, Hou P, Anderson H 3rd, et al. Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med. 2011;183:462–70.PubMed

187.

Esper AM, Moss M, Martin GS. The effect of diabetes mellitus on organ dysfunction with sepsis: An epidemiological study. Crit Care. 2009;13:R18.PubMedPubMedCentral

188.

Alba-Loureiro TC, Munhoz CD, Martins JO, Cerchiaro GA, Scavone C, Curi R, et al. Neutrophil function and metabolism in individuals with diabetes mellitus. Braz J Med Biol Res. 2007;40:1037–44.PubMed

189.

Filgueiras LR Jr, Martins JO, Serezani CH, Capelozzi VL, Montes MB, Jancar S. Sepsis-induced acute lung injury (ALI) is milder in diabetic rats and correlates with impaired NFkB activation. PLoS One. 2012;7:e44987.PubMed

190.

Ahamed K, Epaud R, Holzenberger M, Bonora M, Flejou JF, Puard J, et al. Deficiency in type 1 insulin-like growth factor receptor in mice protects against oxygen-induced lung injury. Respir Res. 2005;6:31.PubMedPubMedCentral

191.

Bellmeyer A, Martino JM, Chandel NS, Scott Budinger GR, Dean DA, Mutlu GM. Leptin resistance protects mice from hyperoxiainduced acute lung injury. Am J Respir Crit Care Med. 2007;175:587–94.PubMed

192.

De Oliveira MJ, Meyer-Pflug AR, Alba-Loureiro TC, Melbostad H, Costa da Cruz JW, Coimbra R, et al. Modulation of lipopolysaccharide-induced acute lung inflammation: role of insulin. Shock. 2006;25:260–6.

193.

Wright JK, Nwariaku FN, Clark J, Falck JC, Rogers T, Turnage RH. Effect of diabetes mellitus on endotoxin-induced lung injury. Arch Surg. 1999;134:1354–9.PubMed

194.

Alba-Loureiro TC, Martins EF, Landgraf RG, Jancar S, Curi R, Sannomiya P. Role of insulin on PGE2 generation during LPS-induced lung inflammation in rats. Life Sci. 2006;78:578–85.PubMed

195.

Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359–67.PubMed

196.

Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449–61.PubMed

197.

Chen HI, Yeh DY, Liou HL, Kao SJ. Insulin attenuates endotoxin-induced acute lung injury in conscious rats. Crit Care Med. 2006;34:758–64.PubMed

198.

Filgueiras LR, Capelozzi VL, Martins JO, Jancar S. Sepsis-induced lung inflammation is modulated by insulin. BMC Pulm Med. 2014;14:177.PubMedPubMedCentral

199.

Liu D, Zeng BX, Zhang SH, Wang YL, Zeng L, Geng ZL, et al. Rosiglitazone, a peroxisome proliferator-activated receptorgamma agonist, reduces acute lung injury in endotoxemic rats. Crit Care Med. 2005;33:2309–16.PubMed

200.

Zmijewski JW, Lorne E, Zhao X, Tsuruta Y, Sha Y, Liu G, et al. Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury. Am J Respir Crit Care Med. 2008;178:168–79.PubMedPubMedCentral

201.

Kawasaki T, Chen W, Htwe YM, Tatsumi K, Dudek SM. DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol. 2018;315:834–45.

202.

Wösten-van Asperen RM, Lutter R, Haitsma JJ, Merkus MP, van Woensel JB, van der Loos CM, et al. ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin. Eur Respir J. 2008;31:363–71.PubMed

203.

Yao HW, Mao LG, Zhu JP. Protective effects of pravastatin in murine lipopolysaccharideinduced acute lung injury. Clin Exp Pharmacol Physiol. 2006;33:793–7.PubMed

204.

Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, Garcia JG. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol. 2005;288:1026–32.

205.

Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J. 2004;25:2243–78.PubMed

206.

Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens. 2001;14:475–86.PubMed

207.

Movahed MR, Hashemzadeh M, Jamal MM. The prevalence of pulmonary embolism and pulmonary hypertension in patients with type II diabetes mellitus. Chest. 2005;128:3568–71.PubMed

208.

Poms AD, Turner M, Farber HW, Meltzer LA, McGoon MD. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest. 2013;144:169–76.PubMed

209.

Benson L, Brittain EL, Pugh ME, Austin ED, Fox K, Wheeler L, et al. Impact of diabetes on survival and right ventricular compensation in pulmonary arterial hypertension. Pulm Circ. 2014;4:311–8.PubMedPubMedCentral

210.

Abernethy AD, Stackhouse K, Hart S, Devendra G, Bashore TM, Dweik R, et al. Impact of diabetes in patients with pulmonary hypertension. Pulm Circ. 2015;5:117–23.PubMedPubMedCentral

211.

Lopez-Lopez JG, Moral-Sanz J, Frazziano G, Gomez-Villalobos MJ, Flores-Hernandez J, Monjaraz E, et al. Diabetes induces pulmonary artery endothelial dysfunction by NADPH oxidase induction. Am J Physiol Lung Cell Mol Physiol. 2008;295:727–32.

212.

Russ RD, Tobin BW. Differential pulmonary vascular effects of streptozotocin diabetes in male and female rats. Proc Soc Exp Biol Med. 1998;217:74–80.PubMed

213.

Pugh ME, Robbins IM, Rice TW, West J, Newman JH, Hemnes AR. Unrecognized glucose intolerance is common in pulmonary arterial hypertension. J Heart Lung Transplant. 2011;30:904–11.PubMedPubMedCentral

214.

Zamanian RT, Hansmann G, Snook S, Lilienfeld D, Rappaport KM, Reaven GM, et al. Insulin resistance in pulmonary arterial hypertension. Eur Respir J. 2009;33:318–24.PubMed

215.

Belly MJ, Tiede H, Morty RE, Schulz R, Voswinckel R, Tanislav C, et al. HbA1c in pulmonary arterial hypertension: a marker of prognostic relevance? J Heart Lung Transplant. 2012;31:1109–14.PubMed

216.

Van Marter LJ, Leviton A, Allred EN, Pagano M, Sullivan KF, Cohen A, et al. Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Pediatrics. 1996;97:658–63.PubMed

217.

Grinnan D, Farr G, Fox A, Sweeney L. The role of hyperglycemia and insulin resistance in the development and progression of pulmonary arterial hypertension. J Diabetes Res. 2016;2016:2481659.PubMedPubMedCentral

218.

Widya RL, van der Meer RW, Smit JW, Rijzewijk LJ, Diamant M, Bax JJ, et al. Right ventricular involvement in diabetic cardiomyopathy. Diabetes Care. 2013;36:457–62.PubMedPubMedCentral

219.

Di Paolo S, Gesualdo L, Ranieri E, Grandaliano G, Schena FP. High glucose concentration induces the overexpression of transforming growth factor-beta through the activation of a platelet-derived growth factor loop in human mesangial cells. Am J Pathol. 1996;149:2095–106.PubMedPubMedCentral

220.

Hua H, Goldberg HJ, Fantus IG, Whiteside CI. High glucose-enhanced mesangial cell extracellular signal-regulated protein kinase activation and alpha1(IV) collagen expression in response to endothelin-1: role of specific protein kinase C isozymes. Diabetes. 2001;50:2376–83.PubMed

221.

Dewachter L, Dewachter C, Belhaj A, Lalande S, Rondelet B, Remmelink M, et al. Insulin-like growth factor-1 contributes to the pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension. Eur Respir J. 2014;44:P316.

222.

Ameshima S, Golpon H, Cool CD, Chan D, Vandivier RW, Gardai SJ, et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res. 2003;92:1162–9.PubMed

223.

Callaghan MJ, Ceradini DJ, Gurtner GC. Hyperglycemia-induced reactive oxygen species and impaired endothelial progenitor cell function. Antioxid Redox Signal. 2005;7:1476–82.PubMed

224.

Kizub IV, Klymenko KI, Soloviev AI. Protein kinase C in enhanced vascular tone in diabetes mellitus. Int J Cardiol. 2014;174:230–42.PubMed

225.

Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the etiology of idiopathic pulmonary fibrosis. Respir Med. 2009;103:927–31.PubMed

226.

Alakhras M, Decker PA, Nadrous HF, Collazo-Clavell M, Ryu JH. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest. 2007;131:1448–53.PubMed

227.

Matsubara T, Hara F. The pulmonary function and histopathological studies of the lung in diabetes mellitus. Nippon Ika Daigaku Zasshi. 1991;58:528–36.PubMed

228.

Farina J, Furio V, Fernandez-Acenero MJ, Muzas MA. Nodular fibrosis of the lung in diabetes mellitus. Virchows Arch. 1995;427:61–3.PubMed

229.

Vracko R, Thorning D, Huang TW. Basal lamina of alveolar epithelium and capillaries: quantitative changes with aging and in diabetes mellitus. Am Rev Respir Dis. 1979;120:973–83.PubMed

230.

Weynand B, Jonckheere A, Frans A, Rahier J. Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration. 1999;66:14–9.PubMed

231.

Enomoto T, Usuki J, Azuma A, Nakagawa T, Kudoh S. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest. 2003;123:2007–11.PubMed

232.

García-Sancho Figueroa MC, Carrillo G, Pérez-Padilla R, Fernández-Plata MR, Buendía-Roldán I, Vargas MH, et al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. Respir Med. 2010;104:305–9.PubMed

233.

Hu Y, Ma Z, Guo Z, Zhao F, Wang Y, Cai L, et al. Type 1 diabetes mellitus is an independent risk factor for pulmonary fibrosis. Cell Biochem Biophys. 2014;70:1385–91.PubMed

234.

Kim YJ, Park JW, Kyung SY, An CH, Lee SP, Chung MP, et al. Association of diabetes mellitus and metabolic syndrome with idiopathic pulmonary fibrosis. Tuberc Respir Dis. 2009;67:113–20.

235.

Kim YJ, Park JW, Kyung SY, Lee SP, Chung MP, Kim YH, et al. Clinical characteristics of idiopathic pulmonary fibrosis patients with diabetes mellitus: the national survey in Korea from 2003 to 2007. J Korean Med Sci. 2012;27:756–60.PubMedPubMedCentral

236.

Hyldgaard C, Hilberg O, Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med. 2014;108:647–53.PubMed

237.

Matsuse T, Ohga E, Teramoto S, Fukayama M, Nagai R, Horiuchi S, et al. Immunohistochemical localisation of advanced glycation end products in pulmonary fibrosis. J Clin Pathol. 1998;51:515–9.PubMedPubMedCentral

238.

Ofulue AF, Kida K, Thurlbeck WM. Experimental diabetes and the lung. I. Changes in growth, morphometry, and biochemistry. Am Rev Respir Dis. 1988;137:162–6.PubMed

239.

Usuki J, Enomoto T, Azuma A, Matsuda K, Aoyama A, Kudoh S. Influence of hyperglycemia to the severity of pulmonary fibrosis. Chest. 2001;120:71S.PubMed

240.

Kida K, Utsuyama M, Takizawa T, Thurlbeck WM. Changes in lung morphologic features and elasticity caused by streptozotocin-induced diabetes mellitus in growing rats. Am Rev Respir Dis. 1983;128:125–31.PubMed

241.

Forgiarini LA Jr, Kretzmann NA, Porawski M, Dias AS, Marroni NA. Experimental diabetes mellitus: oxidative stress and changes in lung structure. J Bras Pneumol. 2009;35:788–91.PubMed

242.

Gumieniczek A, Hopkala H, Wojtowicz Z, Wysocka M. Changes in antioxidant status of lung tissue in experimental diabetes in rabbits. Clin Biochem. 2002;35:147–9.PubMed

243.

Kinalski M, Sledziewski A, Telejko B, Zarzycki W, Kinalska I. Lipid peroxidation and scavenging enzyme activity in streptozotocin- induced diabetes. Acta Diabetol. 2000;37:179–83.PubMed

244.

Oztay F, Kandil A, Gurel E, Ustunova S, Kapucu A, Balci H, et al. The relationship between nitric oxide and leptin in the lung of rat with streptozotocin-induced diabetes. Cell Biochem Funct. 2008;26:162–71.PubMed

245.

Zheng F, Lu W, Wu F, Li H, Hu X, Zhang F. Recombinant decorin ameliorates the pulmonary structure alterations by down-regulating transforming growth factor-beta1/SMADS signaling in the diabetic rats. Endocr Res. 2010;35:35–49.PubMed

246.

Kolahian S, Sadri H, Shahbazfar AA, Amani M, Mazadeh A, Mirani M. The effects of leucine, zinc, and chromium supplements on inflammatory events of the respiratory system in type 2 diabetic rats. PLoS One. 2015;10:e0133374.PubMedPubMedCentral

247.

Carlson EC, Audette JL, Veitenheimer NJ, Risan JA, Laturnus DI, Epstein PN. Ultrastructural morphometry of capillary basement membrane thickness in normal and transgenic diabetic mice. Anat Rec A Discov Mol Cell Evol Biol. 2003;271:332–41.PubMed

248.

Oishi K, Ohkura N, Kasamatsu M, Fukushima N, Shirai H, Matsuda J, et al. Tissue-specific augmentation of circadian PAI-1 expression in mice with streptozotocin-induced diabetes. Thromb Res. 2004;114:129–35.PubMed

249.

Yang JL, Tan Y, Ma ZS, Miao LN, Zhao FL, Cai L. Lung fibrosis in experimental type 1 diabetic mouse model: role of oxidative stress and inflammation. Diabetes. 2010;59:A245.

250.

Wang CM, Hsu CT, Niu HS, Chang CH, Cheng JT, Shieh JM. Lung damage induced by hyperglycemia in diabetic rats: the role of signal transducer and activator of transcription 3 (STAT3). J Diabetes Complicat. 2016;30:1426–33.

251.

Yang J, Tan Y, Zhao F, Ma Z, Wang Y, Zheng S, et al. Angiotensin II plays a critical role in diabetic pulmonary fibrosis most likely via activation of NADPH oxidase-mediated nitrosative damage. Am J Physiol Endocrinol Metab. 2011;301:132–44.

252.

Papinska AM, Soto M, Meeks CJ, Rodgers KE. Long-term administration of angiotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathological remodeling. Pharmacol Res. 2016;107:372–80.PubMedPubMedCentral

253.

Kroll MH, Afshar-Kharghan V. Platelets in pulmonary vascular physiology and pathology. Pulm Circ. 2012;2:291–308.PubMedPubMedCentral

254.

Jagadapillai R, Rane MJ, Lin X, Roberts AM, Hoyle GW, Cai L, Gozal E. Diabetic Microvascular Disease and Pulmonary Fibrosis: The Contribution of Platelets and Systemic Inflammation. Int J Mol Sci. 2016;17.PubMedCentral

255.

Singh S, Bodas M, Bhatraju NK, Pattnaik B, Gheware A, Parameswaran PK, et al. Hyperinsulinemia adversely affects lung structure and function. Am J Physiol Lung Cell Mol Physiol. 2016;310:837–45.

256.

Mexas AM, Hess RS, Hawkins EC, Martin LD. Pulmonary lesions in cats with diabetes mellitus. J Vet Intern Med. 2006;20:47–51.PubMed

Springer Medizin

Diabetic lung disease: fact or fiction?

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Calcium citrate: from biochemistry and physiology to clinical applications

Vasopressin and Copeptin in health and disease

Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease

Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly

Genetics, adaptation to environmental changes and archaic admixture in the pathogenesis of diabetes mellitus in Indigenous Australians